Kiora Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KPRX research report →
Companywww.kiorapharma.com
Kiora Pharmaceuticals, Inc. , a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
- CEO
- Brian Strem
- IPO
- 2015
- Employees
- 12
- HQ
- Encinitas, UT, US
Price Chart
Valuation
- Market Cap
- $11.70M
- P/E
- -1.00
- P/S
- 0.00
- P/B
- 0.79
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.30%
- ROIC
- -62.01%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-10,835,154 · -401.42%
- EPS
- $-2.60 · -379.57%
- Op Income
- $-9,459,247
- FCF YoY
- -217.76%
Performance & Tape
- 52W High
- $4.18
- 52W Low
- $1.76
- 50D MA
- $2.30
- 200D MA
- $2.33
- Beta
- -0.47
- Avg Volume
- 504.83K
Get TickerSpark's AI analysis on KPRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Tosca Melissa | other | 929 |
| Apr 1, 26 | Daniels Eric Joseph | other | 929 |
| Apr 1, 26 | Strem Brian M. | other | 1,906 |
| Mar 6, 26 | Daniels Eric Joseph | other | 6,533 |
| Mar 6, 26 | Daniels Eric Joseph | other | 13,067 |
| Mar 6, 26 | Strem Brian M. | other | 16,733 |
| Mar 6, 26 | Strem Brian M. | other | 33,467 |
| Mar 6, 26 | Tosca Melissa | other | 6,533 |
| Mar 6, 26 | Tosca Melissa | other | 13,067 |
| Mar 3, 26 | Daniels Eric Joseph | other | 238 |
Our KPRX Coverage
We haven't published any research on KPRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KPRX Report →